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Background: Recent randomized controlled trials (RCTs) have called into question
whether percutaneous coronary intervention (PCI) reduces death or myocardial
infarction in patients with stable ischemic heart disease (SIHD). However, several of
these trials randomized an unselected group of patients, including those with and
without objective ischemia.
Methods: We performed a meta-analysis of RCTs comparing PCI with medical
therapy (MT) in pts with either ischemia (identiﬁed on non-invasive testing) or
abnormal fractional ﬂow reserve (FFR), to determine whether PCI reduces all-cause
mortality in this high-risk SIHD cohort.
Results: Four RCTs comparing PCI vs. MT in pts with objective ischemia (or FFR-
equivalent) were found; these trials randomized a total of 1,769 pts with f/u from 7
months to 10 years. The point estimate of the hazard ratio (HR) for mortality following
PCI vs. MT varied from 0.33-0.73, with no trial heterogeneity (I2¼0%). Of note, the
documented ischemia cohort of the COURAGE trial (Am Heart J 2012) comprised
48% of the weight of the included studies. Overall, 28/871 (3.2%) PCI pts died
compared with 54/898 MT pts (6.0%), consistent with a signiﬁcant reduction in all-
cause mortality with PCI (HR 0.56; 95% conﬁdence interval (CI): 0.34-0.93, p¼0.02,
Figure), which remained signiﬁcant when 3 other ineligible RCTs were added which
included a PCI vs MT arm (HR 0.61 [0.42,0.89], p¼0.01).JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrConclusions: Despite conventional conclusions drawn from existing RCT data that
PCI and MT result in comparable survival in SIHD, when analyses are restricted to pts
with objective ischemia (or the FFR equivalent), PCI is associated with a signiﬁcant
and consistent 44% reduction in all-cause mortality compared with MT.
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Background: Studies indicate no clear beneﬁt of early percutaneous coronary inter-
vention (PCI) (<24 hours) in non ST elevation acute coronary syndrome (NSTE-
ACS) patients as compared to delayed PCI (>24 hours). However, high risk NSTE-
ACS patients may beneﬁt from early PCI. We pooled existing data and performed
a meta-analysis.
Methods: Medline, PubMed and abstracts from major cardiology conferences were
searched. Randomized control trials (RCTs) comparing the composite of death and/or
myocardial infarctions (MI) and/or repeat revascularization within 6 months of early
or delayed PCI for high risk patients with NSTE-ACS were included. High risk was
deﬁned as TIMI score >5 or GRACE score >140. The effects of both methods were
analyzed by calculating pooled estimates for death, MI and repeat revascularization.
Analyses were performed for the outcome by using odds ratio (OR) by random effects
model. Heterogeneity among studies was assessed by calculating I00 measure of
inconsistency.
Results: Three studies (ACUITY, ELISA-3 and TIMACS) with a total of 3090
patients met our inclusion criteria. The incidence of the composite of death and/or MI
and/or repeat revascularization was not different between early PCI [207/1422
(14.5%)] as compared to delayed PCI [310/1668(18.6%)], (OR 0.72, 95% CI 0.51-
1.01, P¼0.06).Conclusions: Coronary artery revascularization within 24 hours of presentation does
not reduce composite of death and/or MI and/or repeat revascularization at 6 months
in high risk NSTE-ACS as compared to intervention after 24 hours. More studies are
needed on this subgroup of NSTE-ACS patients.
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Background: Delayed endothelial coverage of stent struts has been linked to late stent
thrombosis, especially after drug-eluting stent implantation. The high-resolution
capability of intravascular optical coherence tomography (OCT) enables visualization
of strut coverage and has been used to quantify coverage at various time points post
implantation. This has the potential application of predicting timing and safety of dual
anti-platelet therapy discontinuation. We aim to summarize all known quantitative
strut level analysis data of clinically implanted coronary stents in human subjects to
date as evaluated by OCT.
Methods: A review of publications and online databases up to February 2013
retrieved 59 eligible articles and abstracts, 1843 initially identiﬁed studies. Data
extracted for bare metal, (BMS), Sirolimus (SES), Paclitaxel (PES), Zotarolimus
(ZES-E & ZES-R) and Everolimus eluting stent (EES) strut coverage and malap-
position was compared between stents at various time intervals post implantation.
Results: 13 abstracts and 46 papers were included in the analysis with studies per-
formed from 1 week to 5 years post implantation. 2,278 patients were studied,
comprising 2,716 stents, 2,044 lesions and strut level data on 532,533 struts, where
data was recorded.
Conclusions: Bare metal stents achieved a threshold of < 2.0% uncovered struts
within 1 month of implantation, SES within 48 months, PES within 60 months,
Endeavor ZES within 2.5 months and EES within 20 months. Resolute ZES have
a 7.4% uncovered strut rate at 13 months post-implantation and lack data beyond this.
OCT enables direct visualization and quantiﬁcation of coronary stent delayed endo-
thelial coverage at a strut level, providing insight into drug eluting stent-speciﬁc
effects on the timing of neo-intimal healing. This may have a role in predicting drug-
eluting-stent speciﬁc safety of dual-antiplatelet therapy cessation.acts/POSTER/Meta-Analyses and Reviews B255
Stent Speciﬁc Temporal Pattern of Coverage and Malapposition as Detected
by OCT
Stent <1m 1m 2m 3-5m 6-8m 9-11m 12-15m 16-20m 21-30m 31-40m 41-50m
51-
60m
BMS
(%)
Unc 13.7 3.5 0.1 0.5 0.7 1.1 1.2 0.3
Mal 12.1 1.2 1.1 0.1 0.1 0.0 0.0
PES (%) Unc 4.9 4.8 4.8 6.5 3.1 10.8 1.0
Mal 2.5 1.8 1.3 1.0 13.8 0.7
SES (%) Unc 15.0 13.4 10.1 10.3 10.5 5.0 4.1 1.8 1.5
Mal 15.5 3.0 2.8 3.6 3.0 4.3 0.3 3.9 1.2
ZES-E
(%)
Unc 90.6 37.3 10.8 0.4 0.4 1.7 3.0 0.2 0.1
Mal 0.9 0.3 0.2 0.1 0.2 0.1 1.7 0.2
ZES-R
(%)
Unc 6.2 7.4 7.4
Mal 0.7 1.5 1.8
EES Unc 62.5 52.6 21.5 3.6 4.9 2.2 0.4
Mal 0.5 1.0 0.8 1.0 1.3 0.6 0.1
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Background: To evaluate the impact of the presence of a chronic total occlusion
(CTO) on short and long term mortality after primary percutaneous coronary inter-
vention (PPCI).
Methods: We performed MEDLINE, Cochrane Controlled Trials Registry and
EMBASE database searches for published articles using predeﬁned terms. Studies that
reported data on the incidence of all-cause mortality in STEMI patients with single- or
multivessel disease (SVD, MVD) with and without CTO were included. Of the 189
studies identiﬁed, 5 articles met the inclusion criteria: 3 observational studies and 2
post-hoc analyses of randomized controlled trials (RCTs).
Results: A total of 10,314 patients were included in the meta-analysis with overall
1160 (11%) patients with CTO. The global analysis demonstrated that CTO was
associated with an over 3-fold increased incidence of mortality at a median follow up
of 36 months compared to patients non-CTO patients (30.4% vs 10.1% OR: 3.24; 95%
conﬁdence interval [CI]: 2.79 to 3.75; p 0.0001) (Figure). This ﬁnding was consistent
in a sub-analysis of studies that reported 30-day follow up (17.6% vs 4.2 OR: 4.3;
95% CI: 3.4 to 5.4 p¼0.001). Cardiac mortality and MACE were also higher in
patients with CTO (14.7% vs 3.7% OR: 4.42; 95% conﬁdence interval [CI]: 3.18 to
6.15; p <0.0001 and 33.5% vs 20.4% OR: 1.97; 95% conﬁdence interval [CI]: 1.56 to
2.47; p <0.0001 respectively).
Conclusions: Coronary chronic total occlusion in the non-culprit artery in patients
presenting with STEMI is associated with poor long-term mortality.TCT-849
Pre-Treatment With High Dose Statin Decreases Cardiovascular Events In
Unstable Patients Undergoing Percutaneous Coronary Intervention: A Meta-
Analysis Of Randomized Controlled Trials
Georges EL-Hayek1, Alexandre M. Benjo2, Eyal Herzog3, Emad Aziz4,
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4Columbia College of Physicians- St Luke's Hospital, New York, NY, 5St Luke's -Roosevelt
Hospital Center, New York, NY
Background: Statin loading prior to percutaneous coronary intervention (PCI) has
been shown to decrease peri-procedural myocardial infarction but less is known
regarding the clinical beneﬁt of pre-procedural statin loading. We aimed to investigate
this hypothesis in stable patients and among patients with Non ST elevation acute
coronary syndromes(NSTE-ACS).B256 JACC Vol 62/18/Suppl B j October 27–NoMethods: We performed a PubMed and Scopus databases search from 1966 through
March 2013 of trials of stable patients and patients with NSTE-ACS treated with high
dose statins prior to PCI. We evaluated the incidence of major cardiac events including
death, spontaneous MI, target vessel revascularization and stent thrombosis. We used
ﬁxed effect analysis when the I2 was up to 40% and the P at least 0.10, otherwise we
used random effect.
Results: Out of 1188 articles, 15 randomized controlled trials were included in this
meta-analysis. Among 3529 patients, 1783 patients were randomized to a loading dose
of statin pre PCI and 1746 patients were given statin therapy initiated only after the
PCI. There was a 43% reduction in clinical events in followup in the group of patients
treated with pre-procedural statin loading, (OR: 0.57, 95%, 0.37-0.89, p¼0.01) When
stratiﬁed according to clinical presentation, this result was only signiﬁcant for those
patients with NSTE-ACS, (OR: 0.18, 95% CI 0.07-0.47, p¼0.0005) (ﬁgure) and was
not noted in the group of patients who underwent PCI for stable angina (OR: 1.0, 95%
CI 0.58-1.72, p¼NS)
Conclusions: Pre-treatment with high dose statins prior to PCI in patients with NSTE-
ACS is associated with a major reduction in clinical events.TCT-850
Intravascular Ultrasound-Guided Versus Angiography-Guided Drug-Eluting
Stent Implantation: Meta-analysis of 3 Randomized Trials and 14 Observational
Studies Involving 26,503 Patients
Jung-Min Ahn1, Young-Rak Cho2, Soo-Jin Kang1, Young-Hak Kim2, Won-Jang Kim1,
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Methods: An unadjusted random-effects meta-analysis was performed in 3 random-
ized and 14 observational studies involving 26,503 patients.
Results: IVUS-guided PCI was signiﬁcantly associated with a longer and bigger
stent implantation and a larger post procedure angiographic minimum lumen
diameter (MLD). The mean difference was 0.18 mm (95% conﬁdence interval [CI]
0.06 to 0.29, P¼0.003), 0.29 mm (95% CI 0.20 to 0.39, P<0.001), 0.33 mm (95%
CI 0.25 to 0.50, P<0.001) for stent length, stent diameter, and MLD, respectively.
Regarding the clinical outcomes, IVUS-guided PCI was associated with a signiﬁ-
cantly lower risk of major adverse cardiac events (MACE) (odds ratio [OR] 0.79,
95% CI 0.67 to 0.94, P¼0.007), death (OR 0.65, 95% CI 0.52 to 0.82, P<0.001),
myocardial infarction (OR 0.55, 95% CI 0.40 to 0.74, P<0.001), repeat revascu-
larization (OR 0.84, 95% CI 0.71 to 0.99, P¼0.04), and stent thrombosis (OR 0.59,
95% CI 0.45 to 0.78, P<0.001).
Conclusions: IVUS-guided PCI was associated with lower risks of adverse clinical
outcomes including the reduction of MACE, death, myocardial infarction, repeat
revascularization, and stent thrombosis. This meta-analysis may encourage the use of
IVUS for PCI in patients undergoing DES implantation.
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Outcomes with ﬁrst- vs. second- generation drug-eluting stents in coronary
chronic total occlusions (CTOs): systematic review and meta-analysis
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Background: To perform a systematic review and meta-analysis of studies reporting
outcomes after ﬁrst- and second- generation drug-eluting stent (DES) implantation in
chronic total occlusions (CTOs).
Methods: As of May 2013, 31 published studies reported outcomes after DES
implantation in CTOs: 13 uncontrolled studies (3161 patients), 3 randomized (220
patients) and 10 non-randomized (2150 patients) comparative studies with bare-metal
stents (BMS), and 2 non-randomized (685 patients) and 3 randomized (489 patients)
comparative studies between ﬁrst and second generation DES. Data were pooled using
random-effects meta-analysis models.vember 1, 2013 j TCT Abstracts/POSTER/Meta-Analyses and Reviews
